IN2014MN01875A - - Google Patents
Info
- Publication number
- IN2014MN01875A IN2014MN01875A IN1875MUN2014A IN2014MN01875A IN 2014MN01875 A IN2014MN01875 A IN 2014MN01875A IN 1875MUN2014 A IN1875MUN2014 A IN 1875MUN2014A IN 2014MN01875 A IN2014MN01875 A IN 2014MN01875A
- Authority
- IN
- India
- Prior art keywords
- compounds
- parp1
- present
- parp
- wnt signalling
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607680P | 2012-03-07 | 2012-03-07 | |
| PCT/GB2013/050561 WO2013132253A1 (en) | 2012-03-07 | 2013-03-07 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01875A true IN2014MN01875A (es) | 2015-07-03 |
Family
ID=47891779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1875MUN2014 IN2014MN01875A (es) | 2012-03-07 | 2013-03-07 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9193689B2 (es) |
| EP (1) | EP2822656B1 (es) |
| JP (1) | JP6082409B2 (es) |
| KR (1) | KR102104144B1 (es) |
| CN (1) | CN104302358B (es) |
| AU (1) | AU2013229229B2 (es) |
| CA (1) | CA2865511A1 (es) |
| DK (1) | DK2822656T3 (es) |
| ES (1) | ES2611504T3 (es) |
| IN (1) | IN2014MN01875A (es) |
| MX (1) | MX346147B (es) |
| RU (1) | RU2696572C2 (es) |
| WO (1) | WO2013132253A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11972017B2 (en) | 2020-10-21 | 2024-04-30 | Verint Americas Inc. | System and method of automated determination of use of sensitive information and corrective action for improper use |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9193689B2 (en) | 2012-03-07 | 2015-11-24 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| PT2882714T (pt) * | 2012-08-08 | 2020-02-19 | Merck Patent Gmbh | Derivados de (aza)isoquinolinona |
| ES2666729T3 (es) | 2013-09-11 | 2018-05-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y su uso terapéutico |
| US9963462B2 (en) | 2015-09-30 | 2018-05-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Sepiapterin reductase inhibitors |
| WO2017093348A1 (en) | 2015-12-02 | 2017-06-08 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| UY37623A (es) | 2017-03-03 | 2018-09-28 | Syngenta Participations Ag | Derivados de oxadiazol tiofeno fungicidas |
| WO2018219773A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Fungicidal compositions |
| US11447481B2 (en) | 2017-06-02 | 2022-09-20 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| KR20200022452A (ko) | 2017-06-28 | 2020-03-03 | 신젠타 파티서페이션즈 아게 | 살진균 조성물 |
| BR112020000470A2 (pt) | 2017-07-11 | 2020-07-21 | Syngenta Participations Ag | derivados oxadiazol microbiocidas |
| WO2019011929A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| BR112020000457A2 (pt) | 2017-07-11 | 2020-07-21 | Syngenta Participations Ag | derivados oxadiazol microbiocidas |
| BR112020000465B1 (pt) | 2017-07-11 | 2024-02-20 | Syngenta Participations Ag | Derivados oxadiazol microbiocidas |
| WO2019012011A1 (en) | 2017-07-12 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| BR112020000463A2 (pt) | 2017-07-13 | 2020-07-21 | Syngenta Participations Ag | derivados oxadiazol microbiocidas |
| EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN112689631A (zh) | 2018-07-16 | 2021-04-20 | 先正达农作物保护股份公司 | 杀微生物的噁二唑衍生物 |
| AR118673A1 (es) * | 2019-04-18 | 2021-10-20 | Syngenta Crop Protection Ag | Procedimiento para la preparación de derivados de oxadiazol microbiocidas |
| EP4033999A2 (en) | 2019-09-26 | 2022-08-03 | Universität Zürich | Left atrial appendage occlusion devices |
| BR112022008282A2 (pt) * | 2019-10-30 | 2022-07-26 | Digmbio Inc | Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo |
| US20240092783A1 (en) | 2021-03-18 | 2024-03-21 | Merck Patent Gmbh | Heteroaromatic compounds for organic electroluminescent devices |
| CN117642375A (zh) * | 2021-05-04 | 2024-03-01 | 德克萨斯大学***董事会 | 茚酮与四氢萘酮-酮或羟基肟作为癌症治疗剂 |
| CN115572262A (zh) * | 2022-10-27 | 2023-01-06 | 厦门沃克沃德医药科技有限公司 | 一种异喹啉衍生物及其制备方法 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851458A (en) | 1955-06-08 | 1958-09-09 | Burroughs Wellcome Co | Diquaternary compounds and the manufacture thereof |
| US3464563A (en) | 1967-02-06 | 1969-09-02 | American Air Filter Co | Liquid filter apparatus |
| US4678500A (en) | 1984-06-29 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
| EP1020445B1 (en) | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Fused pyridine derivatives |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| ATE544750T1 (de) | 2001-09-21 | 2012-02-15 | Bristol Myers Squibb Co | Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| KR20050030636A (ko) * | 2002-07-24 | 2005-03-30 | 교린 세이야꾸 가부시키 가이샤 | 4-(치환된 아릴)-5-하이드록시이소퀴놀리논 유도체 |
| CA2500888C (en) * | 2002-10-01 | 2010-07-13 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| DE60317918T2 (de) | 2002-10-23 | 2009-01-29 | Glenmark Pharmaceuticals Ltd. | Tricyclische verbindungen zur behandlung von entzündlichen und allergischen erkrankungen verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| JP4733023B2 (ja) | 2003-04-16 | 2011-07-27 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤 |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2005075432A1 (ja) | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| WO2005113540A1 (ja) | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| CA2584507C (en) | 2004-10-20 | 2016-04-26 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
| JP5046950B2 (ja) | 2004-10-22 | 2012-10-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃ−ｆｍｓキナーゼのインヒビター |
| ES2314744T3 (es) | 2004-12-16 | 2009-03-16 | F. Hoffmann-La Roche Ag | Derivados de piperazinilpiridina como agentes anti-obesidad. |
| TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| WO2006106812A1 (ja) | 2005-03-31 | 2006-10-12 | Astellas Pharma Inc. | プロパン-1,3-ジオン誘導体又はその塩 |
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| BRPI0615096A2 (pt) * | 2005-08-24 | 2009-07-14 | Inotek Pharmaceuticals Corp | análogos de indenoisoquinolinona e métodos de uso dos mesmos |
| PT2090570E (pt) | 2006-09-05 | 2011-12-29 | Kyowa Hakko Kirin Co Ltd | Derivado de imidazole |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008092231A1 (en) | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| FR2919286A1 (fr) | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009027650A1 (en) | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| WO2009059994A2 (en) | 2007-11-05 | 2009-05-14 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| DE102008019838A1 (de) | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| CN102066360B (zh) | 2008-04-22 | 2013-10-30 | 詹森药业有限公司 | 喹啉或异喹啉取代的p2x7拮抗剂 |
| US8697685B2 (en) | 2008-11-20 | 2014-04-15 | Glaxosmithkline Llc | Chemical compounds |
| BRPI1016266A2 (pt) | 2009-03-06 | 2019-09-24 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| JP5795304B2 (ja) | 2009-03-18 | 2015-10-14 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
| KR102215167B1 (ko) | 2009-04-22 | 2021-02-16 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| CN102666540A (zh) | 2009-10-13 | 2012-09-12 | Msd欧斯股份有限公司 | 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 |
| WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| EP2582680A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| EP2731942B1 (en) | 2011-07-13 | 2015-09-23 | Novartis AG | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| JP5957077B2 (ja) | 2011-07-13 | 2016-07-27 | ノバルティス アーゲー | タンキラーゼ阻害剤として使用するための４−ピペリジニル化合物 |
| EP2731951B1 (en) | 2011-07-13 | 2015-08-19 | Novartis AG | 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors |
| JP6106182B2 (ja) | 2011-11-25 | 2017-03-29 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｐａｒｐ−１阻害剤としての３−フェニル−イソキノリン−１（２ｈ）−オン誘導体 |
| CN106083849A (zh) | 2011-12-31 | 2016-11-09 | 百济神州有限公司 | 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物 |
| SI2797921T1 (en) | 2011-12-31 | 2018-01-31 | Beigene, Ltd. | Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors |
| BR112014018341A8 (pt) | 2012-01-28 | 2017-07-11 | Merck Patent Gmbh | Compostos aza-heterocíclicos |
| US9174980B2 (en) | 2012-01-31 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| CN104093714B (zh) | 2012-02-09 | 2016-08-24 | 默克专利股份公司 | 作为tank和parp抑制剂的四氢-喹唑啉酮衍生物 |
| US9340549B2 (en) | 2012-03-05 | 2016-05-17 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| US9193689B2 (en) | 2012-03-07 | 2015-11-24 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| ES2585044T3 (es) | 2012-03-28 | 2016-10-03 | Merck Patent Gmbh | Derivados de pirazinona bicíclicos |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EA027628B1 (ru) | 2012-05-04 | 2017-08-31 | Мерк Патент Гмбх | Производные пирролотриазинона |
| WO2013177349A2 (en) | 2012-05-25 | 2013-11-28 | Glaxosmithkline Llc | Quinazolinediones as tankyrase inhibitors |
| WO2013182580A1 (en) | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| KR20150016406A (ko) | 2012-06-07 | 2015-02-11 | 에프. 호프만-라 로슈 아게 | 탄키라제의 피라졸로피리미돈 및 피라졸로피리돈 억제제 |
| BR112014031785A2 (pt) | 2012-06-20 | 2017-06-27 | Hoffmann La Roche | composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção |
| KR20150011838A (ko) | 2012-06-20 | 2015-02-02 | 에프. 호프만-라 로슈 아게 | 탄키라아제 억제제로서의 피롤로피라존 |
| PT2882714T (pt) | 2012-08-08 | 2020-02-19 | Merck Patent Gmbh | Derivados de (aza)isoquinolinona |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| KR102200628B1 (ko) | 2012-09-26 | 2021-01-08 | 메르크 파텐트 게엠베하 | Ｐａｒｐ 억제제로서의 퀴나졸리논 유도체 |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
-
2013
- 2013-03-07 US US14/381,712 patent/US9193689B2/en not_active Expired - Fee Related
- 2013-03-07 CN CN201380023162.0A patent/CN104302358B/zh not_active Expired - Fee Related
- 2013-03-07 KR KR1020147026143A patent/KR102104144B1/ko active IP Right Grant
- 2013-03-07 JP JP2014560442A patent/JP6082409B2/ja not_active Expired - Fee Related
- 2013-03-07 WO PCT/GB2013/050561 patent/WO2013132253A1/en active Application Filing
- 2013-03-07 MX MX2014010509A patent/MX346147B/es active IP Right Grant
- 2013-03-07 CA CA2865511A patent/CA2865511A1/en not_active Abandoned
- 2013-03-07 AU AU2013229229A patent/AU2013229229B2/en not_active Ceased
- 2013-03-07 EP EP13709994.1A patent/EP2822656B1/en active Active
- 2013-03-07 ES ES13709994.1T patent/ES2611504T3/es active Active
- 2013-03-07 DK DK13709994.1T patent/DK2822656T3/en active
- 2013-03-07 IN IN1875MUN2014 patent/IN2014MN01875A/en unknown
- 2013-03-07 RU RU2014138194A patent/RU2696572C2/ru not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11972017B2 (en) | 2020-10-21 | 2024-04-30 | Verint Americas Inc. | System and method of automated determination of use of sensitive information and corrective action for improper use |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102104144B1 (ko) | 2020-04-23 |
| DK2822656T3 (en) | 2017-01-30 |
| JP2015512885A (ja) | 2015-04-30 |
| CN104302358B (zh) | 2017-12-05 |
| EP2822656A1 (en) | 2015-01-14 |
| MX2014010509A (es) | 2014-10-14 |
| RU2014138194A (ru) | 2016-04-27 |
| RU2696572C2 (ru) | 2019-08-05 |
| MX346147B (es) | 2017-03-09 |
| ES2611504T3 (es) | 2017-05-09 |
| CA2865511A1 (en) | 2013-09-12 |
| WO2013132253A1 (en) | 2013-09-12 |
| JP6082409B2 (ja) | 2017-02-15 |
| EP2822656B1 (en) | 2016-10-19 |
| AU2013229229A1 (en) | 2014-09-25 |
| US9193689B2 (en) | 2015-11-24 |
| KR20150001734A (ko) | 2015-01-06 |
| CN104302358A (zh) | 2015-01-21 |
| US20150099732A1 (en) | 2015-04-09 |
| AU2013229229B2 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01875A (es) | ||
| PH12019502809A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MD20140109A2 (ro) | Compuşi ai indolului şi indazolului care activează AMPK | |
| NZ700928A (en) | Dna-pk inhibitors | |
| PH12015500825A1 (en) | Substituted benzene compounds | |
| IN2015DN01156A (es) | ||
| MX356205B (es) | Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
| TN2016000238A1 (en) | Tricyclic compounds as anticancer agents. | |
| NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| WO2014028591A3 (en) | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| JO3419B1 (ar) | مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr | |
| JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| MX362855B (es) | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). | |
| PH12014501581A1 (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| MX2016008042A (es) | Derivados de imidazopirazinona. | |
| IN2014CN04671A (es) | ||
| PH12016502133A1 (en) | Substituted tricycle compounds as fgfr inhibitors | |
| IN2015DN01223A (es) |